BCL9-2 Antibody [Alexa Fluor® 532]

• Reactivity: Hu
• Applications: WB
• Clonality: Polyclonal
• Host: Sheep
• Conjugate: Alexa Fluor 532

BCL9-2 Antibody [Alexa Fluor® 532] Summary

• Immunogen: E. coli-derived recombinant human Bcl9-2
  Met38-Val206
  Accession # Q86UU0
• Specificity: Detects endogenous human Bcl9-2 in Western blots.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Sheep
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for BCL9-2 Antibody [Alexa Fluor® 532]

• B-cell CLL/lymphoma 9-like protein
• B-cell CLL/lymphoma 9-like
• B-cell lymphoma 9-like protein
• Bcl92
• Bcl9-2
• BCL9-like protein
• DLNB11
• DLNB11BCL9-2
• nuclear co-factor of beta-catenin signalling
• Protein BCL9-2

Background

Bcl9-2 (B-cell lymphoma 9-like protein; also Bcl9L and B9L) is a 200-220 kDa transcriptional regulator that belongs to the Bcl9 family of proteins. It is expressed in multiple tissues, particularly breast, and serves to recruit Pygopus to the Wnt-pathway beta -catenin-TCF complex in the nucleus. Bcl9-2 and Bcl9 are considered evolutionary duplicates of Legless that perform the same task with different regulation. Human Bcl9-2 is 1499 amino acids (aa) in length. It contains two Pro-rich regions (aa 280-493 and 891-1378). There are four potential alternate start sites at Met879, Met1000, Met708 and Met472. The last two start sites are accompanied by a deletion of aa 1241-1286, and a 62 aa substitution for the C-terminal 167 aa, respectively. Over aa 38-206, human Bcl9-2 is 94% aa identical to mouse Bcl9-2. Bcl9-2 has been identified as a phosphoprotein in several human cancer cell lines and mouse liver.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.